2023 ESC Guidelines for the management of acute coronary syndromes

European Heart Journal, Journal Year: 2023, Volume and Issue: 44(38), P. 3720 - 3826

Published: Aug. 25, 2023

Language: Английский

---

Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies

Pharmacological Reviews, Journal Year: 2021, Volume and Issue: 73(3), P. 924 - 967

Published: June 4, 2021

The endothelium, a cellular monolayer lining the blood vessel wall, plays critical role in maintaining multiorgan health and homeostasis. Endothelial functions include dynamic maintenance of vascular tone, angiogenesis, hemostasis, provision an antioxidant, anti-inflammatory, antithrombotic interface. Dysfunction endothelium presents with impaired endothelium-dependent vasodilation, heightened oxidative stress, chronic inflammation, leukocyte adhesion hyperpermeability, endothelial cell senescence. Recent studies have implicated altered metabolism endothelial-to-mesenchymal transition as new features dysfunction. dysfunction is regarded hallmark many diverse human panvascular diseases, including atherosclerosis, hypertension, diabetes. has also been severe coronavirus disease 2019. Many clinically used pharmacotherapies, ranging from traditional lipid-lowering drugs, antihypertensive antidiabetic drugs to proprotein convertase subtilisin/kexin type 9 inhibitors interleukin 1β monoclonal antibodies, counter part their clinical benefits. regulation by noncoding RNAs provided novel insights into these newly described regulators dysfunction, thus yielding potential therapeutic approaches. Altogether, better understanding versatile (dys)functions cells will not only deepen our comprehension diseases but accelerate effective drug discovery. In this review, we provide timely overview multiple layers function, describe consequences mechanisms identify pathways targeted therapies.

Significance Statement

was initially considered be semipermeable biomechanical barrier gatekeeper health. recent decades, deepened biological led its recognition ubiquitous tissue regulating behavior, innate immunity, cell-cell interactions, wall. cardiovascular, metabolic, emerging infectious diseases. Pharmacotherapies targeting for treatment cardiovascular other

Language: Английский

---

PPAR control of metabolism and cardiovascular functions

Nature Reviews Cardiology, Journal Year: 2021, Volume and Issue: 18(12), P. 809 - 823

Published: June 14, 2021

Language: Английский

---

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial

Nature Medicine, Journal Year: 2021, Volume and Issue: 27(11), P. 1954 - 1960

Published: Oct. 28, 2021

Patients with heart failure and preserved ejection fraction (HFpEF) have a high burden of symptoms functional limitations, poor quality life. By targeting cardiometabolic abmormalities, sodium glucose cotransporter 2 (SGLT2) inhibitors may improve these impairments. In this multicenter, randomized trial patients HFpEF (NCT03030235), we evaluated whether the SGLT2 inhibitor dapagliflozin improves primary endpoint Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CS), measure failure-related health status, at 12 weeks after treatment initiation. Secondary endpoints included 6-minute walk test (6MWT), KCCQ Overall (KCCQ-OS), clinically meaningful changes in KCCQ-CS -OS, weight, natriuretic peptides, glycated hemoglobin systolic blood pressure. total, 324 were to or placebo. Dapagliflozin improved (effect size, 5.8 points (95% confidence interval (CI) 2.3-9.2, P = 0.001), meeting predefined endpoint, due improvements both total symptom score (KCCQ-TS) (5.8 CI 2.0-9.6, 0.003)) physical limitations scores (5.3 0.7-10.0, 0.026)). also 6MWT (mean effect size 20.1 m 5.6-34.7, 0.007)), KCCQ-OS (4.5 1.1-7.8, 0.009)), proportion participants 5-point greater (odds ratio (OR) 1.73 1.05-2.85, 0.03)) reduced weight 0.72 kg 0.01-1.42, 0.046)). There no significant differences other secondary endpoints. Adverse events similar between placebo (44 (27.2%) versus 38 (23.5%) patients, respectively). These results indicate that significantly patient-reported symptoms, exercise function was well tolerated chronic HFpEF.

Language: Английский

---

Association of Glycemic Indices (Hyperglycemia, Glucose Variability, and Hypoglycemia) with Oxidative Stress and Diabetic Complications

Journal of Diabetes Research, Journal Year: 2020, Volume and Issue: 2020, P. 1 - 17

Published: Oct. 12, 2020

Oxidative stress (OS) is defined as a disturbance in the prooxidant-antioxidant balance of cell, favor former, which results antioxidant capacity cell to be overpowered. Excess reactive oxygen species (ROS) production very harmful constituents, especially proteins, lipids, and DNA, thus causing damage cell. has been associated with variety pathologic conditions, including diabetes mellitus (DM), cancer, atherosclerosis, neurodegenerative diseases, rheumatoid arthritis, ischemia/reperfusion injury, obstructive sleep apnea, accelerated aging. Regarding DM specifically, previous experimental clinical studies have pointed fact that oxidative probably plays major role pathogenesis development diabetic complications. It postulated hyperglycemia induces free radicals impairs endogenous defense systems through several different mechanisms. In particular, promotes creation advanced glycation end-products (AGEs), activation protein kinase C (PKC), hyperactivity hexosamine sorbitol pathways, leading insulin resistance, impaired secretion, endothelial dysfunction, by inducing excessive ROS OS. Furthermore, glucose variability OS well, recent evidence suggests also hypoglycemia may playing an important favoring vascular complications OS, inflammation, prothrombotic events, dysfunction. The association these parameters (i.e., hyperglycemia, variability, hypoglycemia) will reviewed here.

Language: Английский

---

Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association

Diabetes Care, Journal Year: 2022, Volume and Issue: 45(7), P. 1670 - 1690

Published: June 1, 2022

Heart failure (HF) has been recognized as a common complication of diabetes, with prevalence up to 22% in individuals diabetes and increasing incidence rates. Data also suggest that HF may develop even the absence hypertension, coronary heart disease, or valvular disease and, such, represents major cardiovascular this vulnerable population; be first presentation many diabetes. Given during past decade, (particularly type 2 diabetes) risen by 30% globally (with expected increase further), burden on health care system will continue rise. The scope American Diabetes Association consensus report designated representation from College Cardiology is provide clear guidance practitioners best approaches for screening diagnosing prediabetes, goal ensure access optimal, evidence-based management all mitigate risks serious complications, leveraging prior policy statements Association.

Language: Английский

---

Role of mitochondrial quality surveillance in myocardial infarction: From bench to bedside

Ageing Research Reviews, Journal Year: 2020, Volume and Issue: 66, P. 101250 - 101250

Published: Dec. 31, 2020

Language: Английский

---

2023 ESC Guidelines for the management of acute coronary syndromes

European Heart Journal Acute Cardiovascular Care, Journal Year: 2023, Volume and Issue: 13(1), P. 55 - 161

Published: Sept. 22, 2023

Journal Article Corrected proof Guidelines 2023 ESC for the management of acute coronary syndromes: Developed by task force on syndromes European Society Cardiology (ESC) Get access Robert A Byrne, Byrne (Ireland) Corresponding authors: A. Department and Cardiovascular Research Institute (CVRI) Dublin, Mater Private Network, Ireland, School Pharmacy Biomolecular Sciences, RCSI University Medicine Health Ireland. Tel: +353-1-2483190, E-mail: [email protected] https://orcid.org/0000-0001-5224-6393 Search other works this author on: Oxford Academic Google Scholar Xavier Rossello, Rossello (Spain) https://orcid.org/0000-0001-6783-8463 J Coughlan, Coughlan https://orcid.org/0000-0001-6086-3279 Emanuele Barbato, Barbato (Italy) https://orcid.org/0000-0002-0050-5178 Colin Berry, Berry (United Kingdom) https://orcid.org/0000-0002-4547-8636 Alaide Chieffo, Chieffo https://orcid.org/0000-0002-3505-9112 Marc Claeys, Claeys (Belgium) https://orcid.org/0000-0002-6628-9543 Gheorghe-Andrei Dan, Dan (Romania) https://orcid.org/0000-0001-9867-2582 R Dweck, Dweck https://orcid.org/0000-0001-9847-5917 Mary Galbraith, Galbraith https://orcid.org/0000-0002-4196-1815 ... Show more Martine Gilard, Gilard (France) Lynne Hinterbuchner, Hinterbuchner (Austria) https://orcid.org/0000-0001-5369-7399 Ewa Jankowska, Jankowska (Poland) https://orcid.org/0000-0002-9202-432X Peter Jüni, Jüni Takeshi Kimura, Kimura (Japan) Vijay Kunadian, Kunadian https://orcid.org/0000-0003-2975-6971 Margret Leosdottir, Leosdottir (Sweden) https://orcid.org/0000-0003-1677-1566 Roberto Lorusso, Lorusso (Netherlands) https://orcid.org/0000-0002-1777-2045 F E Pedretti, Pedretti https://orcid.org/0000-0003-1789-8657 Angelos G Rigopoulos, Rigopoulos (Greece) https://orcid.org/0000-0003-0735-2319 Maria Rubini Gimenez, Gimenez (Germany) https://orcid.org/0000-0003-2384-8250 Holger Thiele, Thiele Pascal Vranckx, Vranckx Sven Wassmann, Wassmann Nanette Kass Wenger, Wenger States America) Borja Ibanez, Ibanez Clinical Department, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain, IIS-Fundación Jiménez Díaz Hospital, CIBERCV, ISCIII, Spain. +3491 4531200, [email protected] https://orcid.org/0000-0002-5036-254X Scientific Document Group Heart Journal. Acute Care, zuad107, https://doi.org/10.1093/ehjacc/zuad107 Published: 22 September history typeset:

Language: Английский

---

Genomics of hypertension: the road to precision medicine

Nature Reviews Cardiology, Journal Year: 2020, Volume and Issue: 18(4), P. 235 - 250

Published: Nov. 20, 2020

Language: Английский

---

Carbohydrate-based drugs launched during 2000−2021

Acta Pharmaceutica Sinica B, Journal Year: 2022, Volume and Issue: 12(10), P. 3783 - 3821

Published: May 23, 2022

Carbohydrates are fundamental molecules involved in nearly all aspects of lives, such as being formating the genetic and energy materials, supporting structure organisms, constituting invasion host defense systems, forming antibiotics secondary metabolites. The naturally occurring carbohydrates their derivatives have been extensively studied therapeutic agents for treatment various diseases. During 2000 to 2021, totally 54 carbohydrate-based drugs which contain carbohydrate moities major structural units approved or diagnostic agents. Here we provide a comprehensive review on chemical structures, activities, clinical trial results these drugs, categorized by indications into antiviral antibacterial/antiparasitic anticancer antidiabetics cardiovascular nervous system other

Language: Английский

---